Dr. Mohd. Rizwan Ahmed is a well-trained hematology and bone marrow transplant specialist with over 9 years of experience in managing different types of malignant and non-malignant hematological conditions. His academic credentials include MBBS, MD (Internal Medicine), and DrNB (Clinical Hematology) degrees from prestigious medical institutions.
He specializes in treating conditions like blood cancer, hemoglobinopathies, bleeding and clotting disorders, bone marrow failures, and autoimmune disorders. Along with conventional treatment approaches, he is also well-versed in administering modern treatments like targeted therapy, immunotherapy, and CAR T-cell therapy for certain types of blood cancer.
Before HCG, he was associated with Seth GS Medical College & KEM Hospital (Mumbai) and Max Super Speciality Hospital (Delhi), where he played an instrumental role in establishing comprehensive BMT programs.
● Dr. Mohd. Rizwan Ahmed is a highly skilled hematology and BMT consultant who can be consulted at HCG Cancer Centre, a leading hospital for cancer treatment in Mumbai.
● He has specialized expertise in administering systemic therapies, namely chemotherapy, immunotherapy, and targeted therapy for different types of blood cancer. He also specializes in different types of bone marrow transplants for cancerous and non-cancerous blood disorders.
● Dr. Rizwan’s areas of specialization include:
⮚ Blood Cancers: Treatment for primary, recurrent, and refractory leukemia, lymphoma, and multiple myeloma cases with novel approaches like targeted therapy, immunotherapy, and bone marrow transplants.
⮚ Hemoglobinopathies: Related and unrelated donor hematopoietic stem cell transplants for conditions like thalassemia and sickle cell anemia.
⮚ Bleeding Disorders: Customized treatment plans for the management of bleeding disorders.
⮚ Bone Marrow Failure Disorders: Comprehensive BMT programs for inherited and acquired bone marrow disorders.
⮚ Autoimmune Disorders: Effective management of autoimmune blood disorders like autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and other autoimmune manifestations of inborn errors of immunity.
⮚ Other Hematological Manifestations: Treatment for hematological manifestations of nutritional deficiencies, pregnancy, trauma, etc.
● Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country. Am J Blood Res. 2021 Jun 15;11(3):290-302.
● Individualized AML Induction with Venetoclax Based Therapy in Unfit Treatment Naïve Patients Aged ≤ 60 Years: A Real World Perspective from India. Blood. 2021;138(Supplement 1):4417.
● Acute pancreatitis in Thalassemia post allogeneic stem cell transplant with Cyclosporine-A as a possible etiology: a report of two cases. IJ Clin Img and med Rew. 2021; 1(1): 1008.
● An ‘Uncommon early lineage switch’ in an MLL rearranged adult B-lineage Acute Lymphoblastic Leukemia to Mixed-phenotypic acute leukemia (B/Myeloid). IJ Clin Img and med Rew. 2021;1(1): 1003
● FLAG based v/s Standard 3 + 7 induction therapy in treatment naïve Acute Myeloid Leukemia: Time to think "beyond anthracyclines." Leuk Res. 2023 Sep;132:107346.
● First Prize in Hematology Quiz at Annual Conference in Mumbai Hematology Group 2018.
● Dr. P. S. Raman Memorial Award for best research paper of the year in 2024.
● Dr. Rizwan has showcased his work at numerous national and international conferences, which has garnered recognition from the attending dignitaries.
⮚ Poster Presentation RGCON 2020: Haploidentical Stem Cell Transplantation in Acute Myeloid Leukemia Using Peripheral Stem Cell Graft: Results from A Tertiary Cancer Care Centre.
⮚ Poster Presentation APICON 2018: Spectrum of Eye Involvement in Patients with Rheumatological Diseases Presenting at a Tertiary Care Centre in India.
⮚ Poster Presentation Hematocon 2024: Role of NGS in T Acute Lymphoblastic Leukemia: a case series.
⮚ Oral Presentation Hematocon 2024: Real-world data outcomes of AZA/VEN induction followed by intermediate-dose cytarabine-based consolidation therapy in AML.
Memberships
● American Society of Transplant and Cellular Therapy: Trainee Membership 2020 Member ID 8450
● American Society of Hematology: International Associate Membership In 2020
● American Society of Clinical Oncology: Membership as a Trainee
HCG Cancer Center -Borivali MUM
View Profile Book an AppointmentHCG Cancer Center -Borivali MUM
View Profile Book an Appointment
MBBS, DNB (Radiation Oncology), Fellowship (Neuro-Oncology)
HCG Cancer Center -Borivali MUM
View Profile Book an Appointment
MD Radiation Oncology (Gold Medal), MBBS
HCG Cancer Center -Borivali MUM
View Profile Book an Appointment
